NEW YORK, Feb. 28 - Robert Rosenthal, president and COO of Boston Life Sciences, has been named to the board of directors for Protedyne, a lab automation supplier for genomics, proteomics, and biopharmaceutical research, the company announced today.
Rosenthal sits on the boards of his own company, which develops diagnostics and therapeutics for cancer and neurological disease; and MolecularWare, which markets the DigitalGenome software for genomic analysis.
Michael Minas has been appointed an interim member of MWG Biotech's internal management board, and will serve on the board until May 21st, the company said today. Minas has been head of MWG Biotech's accounting and financial division since September 2001. He will serve with Thomas Becker, Chairman of the board of management. The company is searching for a permanent member of the two-person management board with a scientific background, R&D knowledge, and operational management or sales and marketing experience.
Jim Lindelien, founder and CTO of TimeLogic, is leaving the company "to pursue new opportunities," the company said Feb. 27. Lindlien, who engineered the company's bioinformatics solution DeCypher, will not be directly replaced, but Roland Luethy, the company's senior bioinformatics research scientist, will head up future development of the DeCypher system, according to TimeLogic.
Steve McPhail has been named the new CEO of Expression Analysis (EA), a microarray analysis firm, the Durham, NC company said Feb. 26. He replaces Donald Holzworth, president and CEO of Analytical Sciences, who has acted as EA's interim CEO since Sept. 2001 when ASI began incubating the company. Holzworth will now serve as chairman of EA's board.
McPhail joins EA from medical device manufacturer ArgoMed, where he served as executive vice president and COO. Prior to joining ArgoMed, McPhail held senior-level sales, marketing and business development positions for Xanthon, TriPath Imaging, Dynex Technologies and Abbott Laboratories.
Affinium Pharmaceuticals of Toronto has appointed new senior directors in chemistry and structural biology, and has promoted three existing senior executives, the company said Feb. 25.
Klaus Fiebig will be the company's new senior director of structural biology, leading the company's structural biology efforts in X-ray crystallography and NMR. Fiebig comes to Affinium from MRPharm of Frankfurt, Germany, which he co-founded.
Henry Pauls is the company's new senior director of medicinal chemistry. He previously worked on asthma and inflammation therapies at Aventis, and held positions at Rhone-Poulenc Rorer and Allexis Biopharmaceuticals.
Additionally, Molly Schmid has been promoted to senior vice president of pre-clinical programs, Raymond Hui has been named vice president of engineering and process development, and Joanne Harack has received the title of vice president, human resources and corporate communications.
Lars Kongsback has been appointed the new CEO of Exiqon, a Danish nucleic acid technology firm, the company said Feb. 24. Kongsback, whose promotion will take effect March 1,, was most recently the company's vice president of business development. He replaces Martin Lavesen, an attorney who has served as acting CEO of the company since 2002 and supervised the company's restructuring.
Kongsback has held positions at Novo Nordisk and at Novozymes, before joining Exiqon in 2000.
Greg Schiffman, chief financial officer for Affymetrix, has been named to the board of directors of Impac Medical Systems of Mountain View, Calif., the company said Feb. 24.
Meanwhile, Schiffman's former colleague Ed Hurwitz has resigned as interim chief executive officer of Aclara Biosciences of Mountain View, Calif. The one-time CFO of Affymetrix turned in notice on Feb. 21, saying he was leaving to concentrate full-time on his job as venture partner for Alta Partners, a
The company's board has brought back Joseph Limber, who stepped down as CEO December 1, to manage the company as part of "the office of the president" along with director Andre Marion. Hurwitz will continue to serve on the board of Aclara, which is focusing on development of its eTag assays.
George Poste was named to the Monsanto board of directors, the company announced Feb. 21. Poste replaces Philip Needleman, the chief scientific officer and senior vice president of Pharmacia.
Poste is the CEO of Health Technology Networks, a consultancy in genomics and healthcare computing. He was formerly CSO and CTO, and president of R&D, for SmithKline Beecham. He is a member of the defense science board of the Department of Defense and is the chairman of the group's task force on bioterrorism.